Monte Rosa Therapeutics, Inc.
GLUE
$18.15
-$0.53-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2,213.02% | 46.87% | 117.54% | 118.53% | 104.55% |
| Total Depreciation and Amortization | 7.23% | 5.96% | 10.90% | 14.51% | 11.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.01% | 8.48% | 5.16% | -5.96% | -0.13% |
| Change in Net Operating Assets | 1,482.81% | -110.05% | 163.19% | -143.50% | -89.70% |
| Cash from Operations | -142.33% | -154.29% | 360.31% | 145.43% | 159.20% |
| Capital Expenditure | -18.85% | -17.85% | 25.08% | 42.79% | 62.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.35% | -140.05% | -1,119.20% | -1,294.42% | -267.96% |
| Cash from Investing | -69.93% | -129.09% | -9,231.31% | -4,831.30% | -297.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 626.98% | -41.55% | -97.44% | -98.12% | 1,744.18% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -146.47% | -100.77% | -100.00% | -100.00% | 86.30% |
| Cash from Financing | 263.54% | -69.31% | -98.92% | -99.20% | 255.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 483.85% | -197.76% | 23.77% | -163.28% | -144.65% |